Many researchers believe the next major advance will come not from shrinking devices further, but from building upward.

A team led by University of Illinois Grainger College of Engineering materials science and engineering professor Qing Cao has demonstrated a new method for stacking multiple layers of silicon electronics directly on top of one another. The approach could dramatically increase computing density, improve performance, and reduce energy consumption while extending the progress that has driven the semiconductor industry for more than half a century.

“Take something as simple as static random-access memory, which is universal in CPUs and GPUs. Today it takes six microelectronic devices called transistors on a single plane to store one bit of information. With vertical integration, you can distribute them across multiple layers. It’s like replacing a sprawling suburb with high-rises: you get the same functionality, but the spatial footprint is reduced while making communication between layers faster and more efficient,” Cao explained.

The researchers report that their process achieves device yields of 98‒100% while using standard single-crystalline silicon, the semiconductor material that underpins modern electronics. The results suggest the technique could eventually be adopted by commercial chip manufacturers.

“Vertical integration is already starting to make its way into commercial devices, particularly in specialized AI hardware, but monolithic integration is what unlocks the full promise of 3D chips,” Cao said. “For the first time, we have met the thermal budget of monolithic 3D integration using standard single-crystalline silicon and delivered unprecedented performance.”

The findings were published in Nature, a journal that rarely features silicon microelectronics research articles.

Why the Semiconductor Industry Is Looking Upward

For roughly 60 years, Moore’s law has guided chip development. The principle predicts that transistor density on integrated circuits will double about every two years, leading to faster and more efficient processors.

That trend has held remarkably well, but it is becoming increasingly difficult to sustain.

“In a sense, we’re hitting a limit imposed by physics,” Cao said. “If you look at the actual size of transistors, they’re not getting smaller, especially in terms of their contacted gate pitch. This is because we’re becoming limited by the intrinsic material properties of silicon and the fundamental rules of quantum mechanics. If we’re going to keep up the trend of increasing processing power of our microprocessors, we have to start thinking beyond just squeezing more devices on a single surface.”

Stacking devices vertically offers an attractive alternative. Instead of continuing to shrink individual transistors, engineers can place multiple layers of circuits on top of one another. This not only creates more room for components but also shortens wiring distances, reducing parasitic capacitance and significantly increasing communication bandwidth between different parts of a chip.

Those advantages are particularly important for artificial intelligence and other data-intensive computing applications.

The Promise of Monolithic 3D Chips

Current commercial 3D chip technologies already use stacking, but they typically involve manufacturing semiconductor devices on separate wafers before bonding them together. Examples include high-bandwidth memory and AMD’s 3D V-Cache technology.

While successful, these methods have limitations. Alignment between layers is relatively coarse, and the vertical connections known as through-silicon vias (TSVs) are comparatively large and sparse.

Monolithic three-dimensional integration takes a different approach. Rather than joining completed wafers, each new device layer is fabricated directly on top of the previous one. This allows much denser vertical connections, smaller distances between layers, and alignment accuracy measured in nanometers.

Researchers have pursued this concept for years because it could increase interlayer connectivity by a factor of 10 to 100 compared with conventional stacking methods.

Solving the Heat Problem

The biggest obstacle to monolithic integration has been temperature.

Producing high-quality crystalline silicon and fabricating high-performance semiconductor devices typically requires temperatures approaching 1,000 degrees Celsius. However, once metal interconnects are already present in a completed circuit layer, such temperatures would destroy them.

“Generally, the industry accepts that once the first layer of circuits is complete, the thermal budget limit for any additional layers is 400 degrees Celsius,” Cao said. “Researchers in both academia and industry have tried to get around this by working with semiconductor materials other than single-crystalline silicon for the upper layers. But the resulting devices all inevitably suffer from issues with performance and reliability.”

Previous efforts have explored alternatives including polycrystalline silicon, amorphous and nanocrystalline metal oxides, carbon nanotubes, and two-dimensional semiconductors. However, those materials often introduce performance limitations or defects that create a mismatch with the silicon transistors in the bottom layer.

Ultrathin Silicon Nanomembranes Enable Low Temperature Manufacturing

The Illinois team developed a process that preserves the advantages of single-crystal silicon while staying well below the thermal limit.

The method begins by creating ultrathin freestanding silicon nanomembranes from a donor wafer. These membranes are then transferred onto a receiving substrate that already contains completed circuitry using a roll laminator. The bonding process requires temperatures of no more than 200 degrees Celsius.

Because the silicon layers retain their crystalline quality, the resulting devices maintain strong performance and reliability while remaining safely within the thermal budget required for monolithic integration.

“Our method is not only easier to implement with lower cost, but it has several advantages over previous approaches to stack silicon wafers,” Cao said. “The membranes we transferred are only 10 nanometers thick or less, compared to the 500 to 700 micrometers thickness of a typical wafer. Because they are thin, these membranes are mechanically flexible to conform to the underlying surface. This conformality helps avoid interfacial defects like voids, which are common when trying to force two rigid wafers together via wafer bonding.”

High Performance With Three Stacked Layers

The researchers also redesigned the transistor architecture.

Traditional transistor manufacturing relies on a process called doping, which introduces impurities into silicon to control electrical behavior. That process usually requires temperatures above 600 degrees Celsius.

To avoid those temperatures, the team used junctionless transistors. In these devices, the silicon is uniformly and heavily doped before the stacking process begins. The extremely thin silicon films still allow effective control by the transistor gate, while the high doping levels help reduce parasitic contact resistance.

Using this strategy, the researchers fabricated three stacked layers containing 625 transistors each. The devices showed strong uniformity and high manufacturing yield.

Their output current densities matched those of conventional silicon transistors fabricated on bulk wafers at much higher temperatures. They also outperformed monolithic devices made from alternative materials by at least a factor of three to four.

The team connected the layers using vertical metal interconnects and successfully demonstrated three-dimensional logic circuits as well as static random-access memory cells.

Toward Commercial Semiconductor Manufacturing

According to Cao, the most significant result may be the scalability of the process.

“But most importantly, we’ve shown that this process is scalable,” Cao said. “You can keep stacking layers beyond the three we demonstrated. And the process will yield high-performing transistors with high yield and low variability. We now have a strong foundation for transferring this technology and demonstrating its immediate promise in an industrial semiconductor foundry.”

The work was carried out through Illinois Grainger Engineering’s Center for Advanced Semiconductor Chips with Accelerated Performance, whose industry partners include IBM, Intel, and the Taiwan Semiconductor Manufacturing Company.

The researchers are now preparing to transfer the technology to an industrial semiconductor foundry, an important step toward bringing true monolithic 3D silicon chips into commercial production.

Additional contributors to the study included Bao Lam, Yung Man Yu, Hyunjun Nam, Hsu-Chih Ni, Shomik Chatterjee, Shaloo Rakheja, and Jian-Min Zhuo.

Funding was provided by the National Science Foundation, industry partners of Illinois Grainger Engineering’s Center for Advanced Semiconductor Chips with Accelerated Performance, and the Silicon Crossroads Microelectronics Commons Hub.

The findings point to a possible way to counter one of the hidden biological effects of working through the night. However, the researchers stress that larger studies are needed before melatonin can be recommended as a long-term strategy for reducing cancer risk in night shift workers.

How Night Shifts Disrupt the Body

Melatonin is best known as the hormone that helps regulate sleep. It rises in darkness and signals to the body that it is time to rest. For people who work overnight, that natural rhythm can be disrupted.

Normal night-time melatonin production is often suppressed in night shift workers. According to the researchers, this may weaken the body’s ability to repair oxidative DNA damage, a type of cellular wear and tear that occurs as part of normal metabolism.

That matters because reduced DNA repair may be one pathway linking long-term night shift work with higher risk for certain cancers. Night shift work has also drawn attention from major health agencies because of its effects on the body’s internal clock, sleep patterns, light exposure, and hormone signaling.

Testing Melatonin in Night Shift Workers

To explore whether melatonin could improve DNA repair, researchers conducted a randomized placebo controlled trial involving 40 night shift workers.

Half of the participants took a 3 mg melatonin pill once daily for 4 weeks. They took the supplement with food about 1 hour before going to sleep during the day. The other half took a 3 mg placebo pill on the same schedule.

All participants had been working at least two consecutive night shifts each week for at least 6 months. Each shift lasted at least 7 hours. None of the participants had sleep disorders or long-term health conditions.

A Marker of DNA Repair Rose During Daytime Sleep

The researchers collected urine samples during two study periods. One sample period took place before the trial began, and the other occurred near the end of the 4 week intervention. Samples were collected during daytime sleep after night shift work and during the following night shift.

Participants also wore activity trackers so the researchers could measure how long they slept during the day.

The team measured urinary levels of 8-OHdG, a marker used to assess oxidative DNA damage repair capacity. Higher urinary levels during sleep were interpreted as a sign of greater repair activity.

Among workers who took melatonin, urinary 8-OHdG levels were 80% higher during daytime sleep compared with those who took the placebo. That suggests melatonin may have boosted DNA repair while participants were sleeping after night work.

However, the same effect was not seen during the subsequent night shift. During that period, urinary 8-OHdG levels did not differ significantly between the melatonin and placebo groups.

Why the Findings Matter

The study offers a possible explanation for how melatonin might help reduce some of the biological strain caused by working at night. The body normally uses sleep and circadian timing to coordinate repair processes. When people work overnight and sleep during daylight hours, that system may not function as well.

Melatonin may help restore part of that lost signal, at least during daytime sleep. Still, the study was small and short, and it did not measure cancer outcomes. It only measured a biomarker related to DNA repair.

Most participants also worked in healthcare, which means the results may not apply to all night shift workers. The researchers were also unable to account for natural light exposure, which can affect melatonin levels in the body.

Newer Context on Night Shift Work

Since the trial was published in 2025, broader research has continued to highlight the complex ways night shift work may affect health. Recent reviews have pointed to several possible mechanisms, including circadian disruption, altered hormone signaling, changes in immune function, metabolic disruption, and impaired DNA repair.

Major scientific assessments have also treated persistent night shift work and light at night as important public health concerns. The International Agency for Research on Cancer has classified night shift work as probably carcinogenic to humans, and the National Toxicology Program has reviewed evidence linking persistent night shift work and light at night with cancer risk.

These findings do not prove that melatonin supplements prevent cancer. Instead, they strengthen the rationale for studying whether restoring melatonin signaling could help reduce some of the biological effects of long-term night work.

Researchers Urge Caution

The researchers emphasize that their findings should be tested in larger studies involving different doses and longer follow up periods.

They write: “Increased oxidative DNA damage due to diminished DNA repair capacity is a compelling mechanism that may contribute to the carcinogenicity of night shift work. Our randomized placebo-controlled trial suggested melatonin supplementation may improve oxidative DNA damage repair capacity among night shift workers.”

And they conclude: “Our findings warrant future larger-scale studies that examine varying doses of melatonin supplements and longer-term impacts of melatonin use. Pending the outcome of such studies, melatonin supplementation may prove to be a viable intervention strategy to reduce the burden of cancer among night shift workers.”

They add: “Assessing long-term efficacy is critical since those who work night shifts for many years would need to consistently consume melatonin supplements over that time frame to maximize the potential cancer prevention benefits.”

For now, the results suggest that melatonin may do more than support sleep. It may also help night shift workers activate a key repair process while their bodies recover during the day. But whether that translates into meaningful long-term protection remains an open question.

The findings, published in JAMA Network, underscore growing concerns about the risks of mixing cannabis and alcohol. Researchers say the results point to a need for better public awareness and more effective ways to identify impaired drivers on the road.

The study also raises questions about current legal standards. According to the researchers, the legal alcohol intoxication threshold used across most of the United States (0.08% breath alcohol level, or BrAC) may not adequately reflect driving impairment when alcohol is combined with cannabis.

“Our findings indicate that co-use of cannabis and alcohol produces significantly greater driving impairment and subjective intoxication than either substance alone,” says the study’s lead author, Austin Zamarripa, Ph.D., assistant professor of psychiatry and behavioral sciences at the Johns Hopkins University School of Medicine. “Importantly, these findings suggest that the interaction between cannabis edibles and alcohol is not merely additive, but may be synergistic in producing impairment, which has important implications for real-world risk.”

Testing Cannabis Edibles and Alcohol Together

To investigate how cannabis edibles and alcohol affect driving, researchers designed a tightly controlled study involving healthy adults between the ages of 21 and 55.

Participants attended multiple outpatient study sessions. During each visit, they received either a cannabis brownie containing THC (10 or 25mg THC) or a placebo brownie. They were also given either an alcoholic beverage or a placebo drink. Alcohol doses were individually adjusted to produce breath alcohol concentrations of either 0.05% or 0.08%.

Thirty volunteers were enrolled in the study, and 25 completed all sessions. Participants had previously used both cannabis and alcohol together within the past year and reported binge drinking within the previous 90 days. To reduce the influence of cannabis tolerance, participants used cannabis relatively infrequently, fewer than three times per week, while still having used it at least once during the past year.

Researchers screened participants through medical and psychiatric evaluations, physical examinations, routine blood tests, and urine drug testing to confirm they were healthy and had not recently used other illicit drugs.

Simulated Driving and Impairment Testing

Before the experimental sessions began, participants completed a separate training visit. During this visit, they became familiar with the driving simulator and other performance assessments to minimize learning effects during the study.

Each participant then completed seven experimental sessions. Depending on the session, they consumed cannabis alone, alcohol alone, cannabis and alcohol together, or placebo versions of both substances. The order of the sessions was carefully balanced among participants to avoid bias.

At the start of each session, participants completed baseline testing that included a simulated driving task, standard field sobriety tests, cognitive and psychomotor assessments, questionnaires about subjective drug effects, and blood sampling to measure THC and its metabolites.

One hour after breakfast, participants consumed either the cannabis brownie or the placebo brownie. Forty-five minutes later, they drank either alcohol or a placebo beverage designed to provide similar sensory cues and help maintain blinding. The beverages were consumed over a 15-minute period.

The same driving, cognitive, and impairment assessments were repeated multiple times throughout the day for as long as 7.5 hours after brownie consumption. Sessions were separated by at least one week to ensure the drugs had cleared participants’ systems before the next visit.

Greater Impairment, But Sobriety Tests Often Missed It

The results showed that combining cannabis edibles with alcohol produced more severe and longer-lasting driving impairment than either substance alone. Participants also reported feeling more intoxicated when they used both substances together.

Despite these effects, standard field sobriety tests only identified significant intoxication during the highest alcohol condition (0.08% BrAC) when compared with placebo. Cannabis-related impairment often went undetected by those tests.

“We designed this study because people are increasingly co-using alcohol with edible cannabis products, yet controlled research has largely focused on smoked cannabis. This is the first controlled study to examine how cannabis edibles and alcohol interact, despite their growing combined use,” says Tory Spindle, Ph.D., the study’s principal investigator and associate professor of psychiatry and behavioral sciences at the Johns Hopkins University School of Medicine. “Consuming typical retail doses of cannabis edibles alongside even low doses of alcohol can produce driving impairment comparable to — or greater than — alcohol alone at the legal limit.”

Implications for Public Safety

As cannabis legalization continues to expand and edible products become more widely available, the researchers say the risks associated with combining cannabis and alcohol deserve greater attention from public health officials, policymakers, and regulators.

They also emphasize the need for additional research to better understand impairment resulting from combined use and to develop more reliable biological and behavioral methods for detecting cannabis-related driving impairment.

Additional Johns Hopkins Medicine researchers involved in the study included Ryan Vandrey, Ph.D., Elise Weerts, Ph.D., David Wolinsky, M.D., and Denis Antoine, M.D.

Measurements suggested the giant planet’s rotation rate was changing over time, as if Saturn were somehow speeding up or slowing down. That puzzling result left scientists searching for answers. Now, researchers using the James Webb Space Telescope (JWST) say they have finally solved the mystery.

The new findings, published in the Journal of Geophysical Research: Space Physics, reveal that Saturn’s spectacular northern lights are at the heart of the phenomenon. The study shows that the planet’s aurora drives a powerful cycle involving heat, winds, and electrical currents that can make Saturn appear to spin at different speeds depending on how it is measured.

Saturn’s Rotation Mystery

The puzzle dates back decades, but it gained renewed attention after observations from NASA’s Cassini spacecraft in 2004 suggested that Saturn’s rotation rate was gradually changing.

That result was difficult to explain because planets do not simply alter their spin rates on short timescales.

In 2021, a team led by Professor Tom Stallard of Northumbria University proposed a different explanation. Their research showed that Saturn’s rotation was not actually changing. Instead, electrical signals linked to the planet’s aurora were being affected by winds in Saturn’s upper atmosphere. Those winds generated electrical currents that altered the auroral signal scientists were using to estimate the planet’s rotation.

While that study explained the misleading measurements, one major question remained unanswered: What was driving those atmospheric winds?

James Webb Maps Saturn’s Aurora

To investigate, Stallard and colleagues from institutions across the United Kingdom and United States turned to the James Webb Space Telescope.

The team observed Saturn’s northern auroral region continuously for an entire Saturnian day. The observations provided a level of detail that previous instruments could not achieve.

Researchers focused on infrared light emitted by a molecule known as trihydrogen cation. This molecule forms in Saturn’s upper atmosphere and serves as a natural indicator of temperature. By analyzing its glow, the team created the most detailed maps ever produced of temperatures and charged particle densities within Saturn’s auroral region.

The improvement in accuracy was dramatic. Earlier measurements carried uncertainties of roughly 50 degrees Celsius, making it difficult to detect subtle changes. JWST’s observations were about ten times more precise, allowing scientists to identify localized patterns of heating and cooling for the first time.

A Self-Sustaining Planetary Heat Engine

The new data closely matched predictions from computer models developed more than a decade ago. However, the models only worked if the source of the atmospheric heating was located exactly where the strongest auroral particles enter Saturn’s atmosphere.

The results indicate that Saturn’s aurora is doing far more than creating a dazzling light show.

Energy deposited by the aurora heats specific regions of the atmosphere. That heating generates winds, which then create electrical currents. Those currents help power the aurora itself, which continues heating the atmosphere and sustaining the entire cycle.

Lead researcher Professor Tom Stallard said: “What we are seeing is essentially a planetary heat pump. Saturn’s aurora heats its atmosphere, the atmosphere drives winds, the winds produce currents that power the aurora, and so it goes on. The system feeds itself.

“For decades, we knew something strange was happening with Saturn’s apparent rotation rate, but we could not explain it. We then showed it was being driven by atmospheric winds, but we still did not know why those winds existed. These new observations, made possible by JWST, finally give us the evidence we needed to close that loop.”

Implications Beyond Saturn

The discovery may have significance far beyond a single planet.

Researchers found evidence that Saturn’s atmosphere and magnetosphere are closely connected. The magnetosphere is the vast region of space shaped by the planet’s magnetic field. Activity in the atmosphere appears to influence conditions in the magnetosphere, while the magnetosphere feeds energy back into the atmosphere.

This ongoing exchange could help explain why the process remains stable over long periods.

According to the researchers, similar interactions may occur on other planets as well.

Professor Stallard added: “This result changes how we think about planetary atmospheres more generally. If a planet’s atmospheric conditions can drive currents out into the surrounding space environment, then understanding what is happening in the stratospheres of other worlds may reveal interactions we have not yet even imagined.”

An International Research Effort

The James Webb Space Telescope is the world’s premier space science observatory. The telescope is designed to study objects throughout the solar system, investigate planets orbiting distant stars, and explore the origins and evolution of the universe. Webb is an international project led by NASA in partnership with ESA (European Space Agency) and CSA (Canadian Space Agency).

The study was conducted by researchers from Northumbria University together with collaborators from Boston University, the University of Leicester, Aberystwyth University, the University of Reading, Imperial College London, Lancaster University, and Johns Hopkins University Applied Physics Laboratory. Funding for the research was provided by the Science and Technology Facilities Council (STFC).

As the human body develops from an embryo into a fetus and eventually an infant, neurons form complex communication networks between the brain and spinal cord. These signals travel through axons, the long nerve fibers that allow neurons to send messages and control muscle movement.

Over time, however, the central nervous system largely loses its ability to regrow damaged axons. As a result, injuries to the brain or spinal cord often become permanent, leading to serious disabilities such as paralysis or loss of movement. This loss of regenerative ability is also linked to neurological diseases including motor neurone disease and multiple sclerosis.

Mini Human Brain and Spinal Cord Models

In 2021, Dr. András Lakatos and his colleagues at the University of Cambridge developed miniature human brain models using stem cells taken from patients. These pea-sized “brain organoids” resembled parts of the cerebral cortex and allowed researchers to study molecular changes linked to motor neurone disease and explore ways to prevent them.

Now, in a new study published in Cell Reports, the researchers expanded on that work by building a miniature version of the connected human brain and spinal cord system.

Because the brain and spinal cord are separate but connected structures in the body, the team kept the organoids physically apart in the lab. They then observed axons from the brain tissue growing across the gap and connecting with the spinal cord tissue. The resulting neural circuit was functional enough to trigger contractions in tiny clusters of muscle cells.

Nerve Regrowth Declines During Development

The scientists maintained these miniature systems in the lab for more than a year. They discovered that until about day 150 of development, roughly corresponding to the middle stage of pregnancy, damaged axons could still regrow. After that point, the neurons showed a major decline in their ability to regenerate.

George Gibbons from the Department of Clinical Neurosciences at the University of Cambridge and first author of the study said: “Neurons taken from less mature organoids regrew long fibers after injury, but those from more mature organoids showed a sharp drop in their ability to regrow. In other words, poor regeneration is built into human neurons as they mature in the central nervous system.”

The team analyzed gene activity in neurons that connect the brain and spinal cord. Their work revealed a network of genes that acts like a biological switch, limiting axon growth as neurons mature and form synapses.

Remarkably, when researchers blocked key regulators within this network, the neurons regained the ability to grow axons again.

Existing Drug Boosted Nerve Regrowth

The researchers also searched a database of drug compounds to identify medicines that affect this newly identified gene network. One promising candidate was lynestrenol, a hormone drug currently approved for certain menstrual disorders and contraceptive use.

When the drug was tested on damaged neurons, it significantly improved axon regrowth.

The scientists noted that scar tissue and inflammation can also interfere with nerve repair after injury. However, understanding the neuron-specific biological mechanisms that limit regeneration remains critically important. Previous evidence has shown that younger neurons can grow through environments that normally block repair at injury sites.

Senior author Dr. András Lakatos, who led the study at the Department of Clinical Neurosciences, said: “When the brain and spinal cord are damaged, the nerve fibers that carry movement signals from the brain to the spinal cord rarely grow back. That’s why paralysis is usually permanent. But we didn’t know exactly when the ability of axons to regenerate becomes limited. Our model provides a good indication that this block happens during development, and it can still be reversed after this point.

“Lynestrenol itself may not be the answer to spinal cord repair, but it shows us that, in principle, it should be possible to directly target human neurons and regenerate their axons. Although we still need to show that this strategy will also help to re-establish appropriate connections between the brain and spinal cord cells, this gives us hope that one day we may be able to treat conditions previously thought untreatable.”

Why Human Organoids Matter

Organoid technology is becoming increasingly valuable for studying human biology and disease. While animal models such as mice and rats remain useful in research, important biological differences limit how accurately they reflect human nervous system function.

Human stem cell-derived organoids can more closely reproduce human biology, helping bridge the gap between animal experiments and real patient outcomes.

Dr. Lakatos added: “Much of what we know about nerve regeneration comes from rodents, whose neurons behave differently from human neurons. Our sophisticated organoid models help bridge the knowledge gap from animal models to what we see in patients. They are also an important contribution to efforts to reduce the use of animals in research.”

Researchers at the University of Cambridge are already using organoids for a wide range of medical studies, including efforts to repair damaged livers, investigate Crohn’s disease in children, and study the earliest stages of pregnancy.

The research was funded by the UK Research and Innovation Medical Research Council and Spinal Research.

Alzheimer’s disease is the most common form of dementia, a condition that gradually damages memory, thinking, and behavior. For years, most Alzheimer’s research has focused on the buildup of amyloid plaques and tau tangles in the brain. These abnormal protein clumps are considered hallmark signs of the disease. However, many researchers now believe chronic inflammation in the brain may also be a key factor driving nerve cell damage.

CBD and Brain Inflammation

Inflammation is part of the body’s natural immune response. In the brain, immune cells normally help protect neurons and clear away harmful debris. But when inflammation becomes chronic, it can begin damaging healthy brain tissue instead. This ongoing immune overactivation, often called neuroinflammation, has been linked to Alzheimer’s disease and several other neurological disorders.

In a new study published in eNeuro, researchers led by Babak Baban from Augusta University investigated whether CBD could help calm this damaging inflammatory response in the brain.

The team used a well-established mouse model of Alzheimer’s disease and delivered CBD through inhalation. They then examined how the compound affected immune activity and inflammatory signaling in the central nervous system, which includes the brain and spinal cord.

Researchers Identify Changes in Key Immune Pathways

Using a variety of molecular and genetic tests, the scientists found that CBD lowered the activity of several important regulators involved in neuroinflammation. The treatment was also associated with reduced levels of proinflammatory molecules, which are substances that can worsen inflammation and contribute to tissue damage.

The researchers also identified specific immune-related pathways that appeared to interact with CBD. These findings suggest the compound may influence multiple biological systems involved in Alzheimer’s disease.

“Alzheimer’s work has long centered on plaques and tangles,” says Baban. “But our study shows that chronic autoinflammation is also a core driver of the disease. What’s exciting is that CBD not only calms this immune overactivation but, in earlier work, we’ve shown it can also help clear plaques and tangles through a different mechanism. Together, this points to a multitarget approach with real therapeutic potential.”

A Growing Interest in Multi-Target Alzheimer’s Treatments

Scientists have increasingly explored treatments that target more than one aspect of Alzheimer’s disease at the same time. Because the condition involves many overlapping biological changes, including inflammation, protein buildup, and neuron damage, researchers believe a multitarget strategy may prove more effective than focusing on a single pathway alone.

Although the findings are promising, the study was conducted in mice, not humans. More research and clinical trials will be needed before scientists know whether CBD could become a safe and effective treatment for people with Alzheimer’s disease.

Still, the results add to growing evidence that controlling brain inflammation may become an important part of future Alzheimer’s therapies.